|
Home
|
|
Symptoms
|
|
Live Discussion
|
|
Diagnosis
|
|
Treatment
|
|
World-wide Support Finder
|
|
Books/Video
|
|
Research
|
|
Lymelinks
|
|
Contact
|
|
Pets & Lyme
|
|
DONATIONS
|
|
Drug Info
|
|
Medical Dictionary
|
|
Board of Directors
|
Click on the graphic to vote for this
site as a Starting Point Hot Site.
|
|
|
No Warranties or Representations
Lyme Disease symptoms vary from person to person. (lymes disease lyme's disease lime disease limes disease)
The data and information presented in this web site are presented in good faith and believed to be accurate regarding Lyme disease (commonly misspelled lymes disease lyme's disease lime disease limes disease) and other related diseases. Any and all liability for the content or any omissions including any inaccuracies, errors, or misstatements in such data or information is expressly disclaimed. The web site is compiled for the sole purpose of informing community members of resources and information pertaining to Lyme Borreliosis Disease and its coinfections. Lyme disease symptoms may vary from person to person.
The Canadian Lyme Disease Foundation, Directors and members are not liable for any direct or indirect damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action arising out of or in connection with the use or performance of information available from this website.
Consult a qualified Lyme ( Borreliosis ) Disease literate doctor for medical advice if Lyme Disease is suspect to discuss your Lymes Disease Symptoms.
|
Wien Klin Wochenschr. 2006 Nov;118(21-22):696-701
Doxycycline versus ceftriaxone for the treatment of patients with
chronic Lyme borreliosis.
* Ogrinc K,
* Logar M,
* Lotric-Furlan S,
* Cerar D,
* Ruzic-Sabljic E,
* Strle F.
Department of Infectious Diseases, University Medical Center
Ljubljana, Slovenia, katarina.ogrinc1@guest.arnes.si.
BACKGROUND:
Therapeutic guidelines for treatment of late
manifestations of Lyme borreliosis have not yet become well established.
Patients with symptoms suggesting central nervous system involvement are
often treated with courses of intravenous ceftriaxone. This is an
expensive treatment approach with potentially severe side effects. We
compared the efficacy, side effects and costs of doxycycline and
ceftriaxone in the treatment of such patients.
PATIENTS AND METHODS:
Adult patients qualified for the study if they
had nonspecific symptoms suggesting central nervous system involvement
for more than six months (but without overt clinical signs of the
involvement), had positive serum borrelial antibody titers and/or
erythema migrans prior to the onset of symptoms, had not been previously
treated with antibiotics and did not have pleocytosis in the
cerebrospinal fluid. Patients were given either 100 mg of oral
doxycycline twice daily for 4 weeks (23 patients) or 2 g of intravenous
ceftriaxone daily for 2 weeks followed by 100 mg of doxycycline twice
daily for another 2 weeks (23 patients). Clinical outcome was assessed
during a 12-month follow-up period.
RESULTS:
Improvement in the frequency and/or the intensity of
symptoms was reported by more than two-thirds of the 46 patients enroled
in the study. The two treatment regimens were found to be
correspondingly effective. Photosensitivity reactions and
gastrointestinal symptoms were noted more often among patients receiving
doxycycline than in those receiving ceftriaxone. Treatment with
doxycycline proved to be much cheaper than with ceftriaxone.
CONCLUSIONS:
In patients with previously untreated chronic Lyme
borreliosis with symptoms suggesting central nervous system involvement
but without overt clinical signs of it, and without pleocytosis in the
cerebrospinal fluid, treatment with doxycycline is as effective as with
ceftriaxone. Treatment with doxycycline is cheap and relatively safe,
but gastrointestinal symptoms and photosensitivity reactions can be
expected more often than with ceftriaxone.
TOP
|
|
| | |
